Metasyn has appointed Michael D. Webb as president and CEO ofthe privately held Cambridge, MA, contrast agent developer. Webbassumes the chief executive position from Metasyn founder RandallB. Lauffer, who will remain chair and chief scientific officer.
Metasyn has appointed Michael D. Webb as president and CEO ofthe privately held Cambridge, MA, contrast agent developer. Webbassumes the chief executive position from Metasyn founder RandallB. Lauffer, who will remain chair and chief scientific officer.
Webb comes to Metasyn from Ciba-Corning Diagnostics, wherehe was senior vice president of worldwide marketing and strategicplanning.
The appointment of Webb represents a step in the company'seffort to commercialize its products, which are in advanced preclinicalstudies, according to the firm. Metasyn is developing MS-323,an MRI blood-pool agent that binds reversibly to albumin.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.